Regencell Bioscience Holdings Limited RGC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.75M | 2.75M | 2.46M | 2.46M | 675.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.19M | 3.19M | 2.67M | 2.67M | 896.10K |
| Operating Income | -3.19M | -3.19M | -2.67M | -2.67M | -896.10K |
| Income Before Tax | -3.19M | -3.19M | -2.66M | -2.66M | -865.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.19M | -3.19M | -2.66M | -2.66M | -865.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.19M | -3.19M | -2.66M | -2.66M | -865.30K |
| EBIT | -3.19M | -3.19M | -2.67M | -2.67M | -896.10K |
| EBITDA | -3.17M | -3.17M | -2.65M | -2.65M | -883.10K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 494.72M | 494.72M | 494.49M | 494.49M | 494.49M |
| Average Diluted Shares Outstanding | 494.72M | 494.72M | 494.49M | 494.49M | 494.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |